Mehr lesen
Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs.
Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics.
Zusammenfassung
A timely primer on the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery.
Zusatztext
From Reviews of the First Edition...
"...strongly recommended both to scientists already engaged in antisense research and to newcomers alike." -Trends in Biotechnology
"...enables an appreciation of the exciting possibilities this field offers for the development of new uniquely selective therapeutic agents via precisely designed inhibitors of the expression of disease associated genes." -Journal of Medicinal Chemistry
Reviews from the Second Edition...
"This book does an excellent job of showing the reader that antisense oligonucletoids could be valuable therapeutic drugs in the future." - Doody's Health Sciences Book
